Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Efficacy of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

NCT06015048 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT06015048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06015048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Efficacy of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 11, 2023
Completion date
December 29, 2026
Enrollment
364 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

her2-expressing advanced solid tumors